Abstract
Background: Preliminary studies have shown that 99mTc-hexakis-2-methoxyisobutylisonitrile (MIBI) is an interesting tracer for various tumors. The aim of this study was to determine the feasibility of using 99mTc-MIBI as a diagnostic and staging procedure for lung cancer. Methods: We prospectively compared the results of biopsy with 99mTc-MIBI imaging in patients with potentially resectable lung lesions (stages IIIA or lower). In the patients with radiopharmaceutical uptake, the staging provided by CT was compared with that obtained with 99mTc-MIBI. Results: Ninety-nine of the 116 patients examined had lung cancer. For the diagnosis of malignancy, the specificity of 99mTc-MIBI was 100%, sensitivity was 89.8%, positive predictive value was 100%, negative predictive value was 62.9%, and accuracy was 91.4%. In the 87 patients with radiopharmaceutical uptake in their lung cancer, the values for the specificity and sensitivity of 99mTc-MIBI in the detection of mediastinal lymph node metastases were 100% and 54.5%, respectively. The corresponding values for CT in the same patients were 87.6% and 63.3%, respectively. The difference in specificity is statistically significant (p = 0.011). Conclusions: This study demonstrates that 99mTc-MIBI provides significant diagnostic and staging information in patients with lung lesions. The high specificity and positive predictive value of 99mTc-MIBI suggest that this radiopharmaceutical could be a very useful tool for the diagnosis of lung cancer, especially in consideration of its low costs and wide availability.
| Original language | English |
|---|---|
| Pages (from-to) | 1361-1364 |
| Number of pages | 4 |
| Journal | Chest |
| Volume | 122 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2002 |
Fingerprint
Keywords
- Tc-hexakis-2-methoxyisobutylisonitrile
- Lung cancer
- Staging
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Role of 99mTc-hexakis-2-methoxyisobutylisonitrile in the diagnosis and staging of lung cancer. / Nosotti, Mario; Santambrogio, Luigi; Gasparini, Massimo; Baisi, Alessandro; Bellaviti, Nadia; Rosso, Lorenzo.
In: Chest, Vol. 122, No. 4, 2002, p. 1361-1364.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Role of 99mTc-hexakis-2-methoxyisobutylisonitrile in the diagnosis and staging of lung cancer
AU - Nosotti, Mario
AU - Santambrogio, Luigi
AU - Gasparini, Massimo
AU - Baisi, Alessandro
AU - Bellaviti, Nadia
AU - Rosso, Lorenzo
PY - 2002
Y1 - 2002
N2 - Background: Preliminary studies have shown that 99mTc-hexakis-2-methoxyisobutylisonitrile (MIBI) is an interesting tracer for various tumors. The aim of this study was to determine the feasibility of using 99mTc-MIBI as a diagnostic and staging procedure for lung cancer. Methods: We prospectively compared the results of biopsy with 99mTc-MIBI imaging in patients with potentially resectable lung lesions (stages IIIA or lower). In the patients with radiopharmaceutical uptake, the staging provided by CT was compared with that obtained with 99mTc-MIBI. Results: Ninety-nine of the 116 patients examined had lung cancer. For the diagnosis of malignancy, the specificity of 99mTc-MIBI was 100%, sensitivity was 89.8%, positive predictive value was 100%, negative predictive value was 62.9%, and accuracy was 91.4%. In the 87 patients with radiopharmaceutical uptake in their lung cancer, the values for the specificity and sensitivity of 99mTc-MIBI in the detection of mediastinal lymph node metastases were 100% and 54.5%, respectively. The corresponding values for CT in the same patients were 87.6% and 63.3%, respectively. The difference in specificity is statistically significant (p = 0.011). Conclusions: This study demonstrates that 99mTc-MIBI provides significant diagnostic and staging information in patients with lung lesions. The high specificity and positive predictive value of 99mTc-MIBI suggest that this radiopharmaceutical could be a very useful tool for the diagnosis of lung cancer, especially in consideration of its low costs and wide availability.
AB - Background: Preliminary studies have shown that 99mTc-hexakis-2-methoxyisobutylisonitrile (MIBI) is an interesting tracer for various tumors. The aim of this study was to determine the feasibility of using 99mTc-MIBI as a diagnostic and staging procedure for lung cancer. Methods: We prospectively compared the results of biopsy with 99mTc-MIBI imaging in patients with potentially resectable lung lesions (stages IIIA or lower). In the patients with radiopharmaceutical uptake, the staging provided by CT was compared with that obtained with 99mTc-MIBI. Results: Ninety-nine of the 116 patients examined had lung cancer. For the diagnosis of malignancy, the specificity of 99mTc-MIBI was 100%, sensitivity was 89.8%, positive predictive value was 100%, negative predictive value was 62.9%, and accuracy was 91.4%. In the 87 patients with radiopharmaceutical uptake in their lung cancer, the values for the specificity and sensitivity of 99mTc-MIBI in the detection of mediastinal lymph node metastases were 100% and 54.5%, respectively. The corresponding values for CT in the same patients were 87.6% and 63.3%, respectively. The difference in specificity is statistically significant (p = 0.011). Conclusions: This study demonstrates that 99mTc-MIBI provides significant diagnostic and staging information in patients with lung lesions. The high specificity and positive predictive value of 99mTc-MIBI suggest that this radiopharmaceutical could be a very useful tool for the diagnosis of lung cancer, especially in consideration of its low costs and wide availability.
KW - Tc-hexakis-2-methoxyisobutylisonitrile
KW - Lung cancer
KW - Staging
UR - http://www.scopus.com/inward/record.url?scp=0036428944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036428944&partnerID=8YFLogxK
U2 - 10.1378/chest.122.4.1361
DO - 10.1378/chest.122.4.1361
M3 - Article
C2 - 12377865
AN - SCOPUS:0036428944
VL - 122
SP - 1361
EP - 1364
JO - Chest
JF - Chest
SN - 0012-3692
IS - 4
ER -